Top in endocrinology: Important updates on anti-obesity medications
Click Here to Manage Email Alerts
Anti-obesity medications may need to be used on a long-term basis, but intermittent therapy can also lead to weight loss and health benefits, a speaker said.
It was the top story in endocrinology last week.
Another top story was about how adults with obesity tirzepatide had decreased energy intake and reduced appetite more than those receiving liraglutide.
Read these and more top stories in endocrinology below:
Intermittent therapy may be a ‘practical strategy’ for maintaining weight loss
People with obesity who are prescribed anti-obesity medications may need to use the agents for life, but intermittent therapy can still confer health benefits, . Read more.
Tirzepatide reduces appetite, food cravings without increasing dietary restraint
Adults with overweight or obesity receiving tirzepatide have a decrease in appetite, food craving and other eating behaviors, according to a speaker at ObesityWeek. Read more.
Teplizumab preserves beta-cell function for children with new-onset type 1 diabetes
Children with new-onset type 1 diabetes had better preservation of beta-cell function with two 12-day courses of teplizumab compared with those receiving placebo, according to findings published in The New England Journal of Medicine. Read more.
Tirzepatide induces more than 19% weight loss for adults with obesity and MC4R deficiency
Adults with obesity and a genetic mutation that causes deficiency in the melanocortin-4 receptor (MC4R) pathway lost a similar amount of weight with tirzepatide as adults without a genetic mutation, according to a speaker. Read more.
FDA expands indication for vosoritide to include children of all ages with achondroplasia
The FDA has expanded its accelerated approval of an injectable therapy for treating achondroplasia to include children of all ages, according to a press release. Read more.
People with Bardet-Biedl syndrome lower metabolic syndrome score with setmelanotide
Setmelanotide may lower the risk for metabolic syndrome for people with a rare monogenic form of obesity, according to data presented at ObesityWeek. Read more.